Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RCKT

Rocket Pharmaceuticals Inc

May 26 • 09:35AM ET

3.00

+0.04 1.35 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: RGNX VYGR QURE EDIT SLDB

| Held by: VTI XBI IWM VXF IBB IWN VTWO FESM SCHA DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.88	Insider Own	5.17%	Shs Outstand	109.12M	Perf Week	-2.28%
Market Cap	327.58M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-0.96%	Shs Float	103.55M	Perf Month	-14.77%
Enterprise Value	207.96M	PEG	-	EPS next Q	1.02	Inst Own	89.46%	Short Float	20.81%	Perf Quarter	-29.41%
Income	-209.38M	P/S	-	EPS this Y	85.64%	Inst Trans	5.94%	Short Ratio	6.37	Perf Half Y	5.63%
Sales	0.00M	P/B	1.38	EPS next Y	-341.97%	ROA	-55.36%	Short Interest	21.55M	Perf YTD	-14.53%
Book/sh	2.18	P/C	2.27	EPS next 5Y	22.83%	ROE	-64.41%	52W High	6.43 -53.34%	Perf Year	-52.15%
Cash/sh	1.32	P/FCF	-	EPS past 3/5Y	14.88% 4.46%	ROIC	-80.57%	52W Low	2.19 36.99%	Perf 3Y	-85.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.39% 6.99%	Perf 5Y	-92.89%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	28.56%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-91.66%
Dividend Ex-Date	-	Quick Ratio	6.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	35.91	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	6.12	EPS Q/Q	23.82%	SMA20	-11.47%	Beta	0.48	Target Price	9.30
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-18.84%	Rel Volume	0.77	Prev Close	2.96
Employees	202	LT Debt/Eq	0.09	Earnings	May 07 AMC	SMA200	-16.01%	Avg Volume	3.38M	Price	3.00
IPO	Feb 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.24% -	Trades		Volume	162,026	Change	1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Downgrade	JP Morgan	Neutral → Underweight
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy	$10
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral	$4
May-30-25	Downgrade	Evercore ISI	Outperform → In-line	$5
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$8
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold	$2.50
May-28-25	Downgrade	Goldman	Neutral → Sell	$2
May-27-25	Downgrade	TD Cowen	Buy → Hold
May-27-25	Downgrade	Needham	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Dec-30-24	Initiated	Wedbush	Outperform	$32
Dec-18-24	Initiated	Jefferies	Buy	$29
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35

Show Previous Ratings

May-07-26 04:08PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
04:00PM	Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
Apr-29-26 05:34AM	Rocket to sell PRV for $180m to advance gene therapy pipeline (Hospital Management)
Apr-28-26 07:00AM	Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher (Business Wire)
Mar-27-26 02:48PM	Nasdaq slides into correction amid Iran tensions and oil surge (Proactive) -19.62%
09:56AM	Loading…
09:56AM	Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI (Proactive)
07:00AM	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Mar-03-26 01:15PM	Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances (Proactive)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) +10.60%
Feb-26-26 04:04PM	Rocket Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress (Business Wire)
Feb-23-26 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) +5.56%
Feb-18-26 07:44PM	Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery (Insider Monkey) +8.41%
Jan-05-26 07:00AM	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 11:10PM	Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position (Insider Monkey)
11:57AM	Loading…
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-25-25 07:00AM	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-18-25 09:41AM	Amazon downgraded, Alphabet upgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 04:09PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Oct-26-25 06:43AM	Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? (Insider Monkey)
Oct-15-25 11:31AM	RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy (Zacks)
Oct-14-25 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) +23.05%
Oct-10-25 04:00PM	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.81%
Oct-03-25 11:33AM	Rocket ditches blood disorder gene therapy in ongoing pipeline pivot (Pharmaceutical Technology)
Aug-28-25 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
07:10AM	Rocket to relaunch rare disease trial after FDA approval (Clinical Trials Arena)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com) +28.87%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Loading…
07:00AM	Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease (Business Wire)
06:46AM	Rocket can resume gene therapy trial after FDA lifts hold (BioPharma Dive)
Aug-19-25 12:09AM	Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating (Insider Monkey)
Aug-17-25 11:41PM	Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform (Insider Monkey)
Aug-07-25 04:07PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.44%
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Aug-06-25 04:24PM	Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 (Newsfile)
Aug-05-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-30-25 04:37PM	Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025 (Newsfile)
01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com)
Jul-29-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-24-25 07:00AM	Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -8.98%
Jul-17-25 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy (Business Wire) +16.78%
Jul-15-25 08:58AM	Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701 (Insider Monkey) -7.87%
Jul-10-25 09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +5.71%
09:00AM	Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
07:25AM	Rocket Pharmaceuticals receives FDA clearance of RP-A701 (TipRanks)
Jun-30-25 07:00AM	Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy (Business Wire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:00AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
May-28-25 06:00PM	Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow (Insider Monkey) +6.44% +5.65%
01:20PM	William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback (Insider Monkey)
11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
May-27-25 08:01PM	Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death (Insider Monkey) -62.84%
11:50AM	Top Stock Movers Now: Tesla, AutoZone, Newmont, and More (Investopedia)
11:35AM	Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies (Investopedia)
10:37AM	CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers (Yahoo Finance Video)
07:00AM	Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease (Business Wire)
May-15-25 03:15PM	Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire) +11.07%
May-13-25 08:54AM	Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey) -5.50%
May-09-25 04:30PM	Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-08-25 04:01PM	Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire) +5.07%
Apr-16-25 11:59AM	Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz (TipRanks) -5.82%
Apr-10-25 11:16AM	Rocket Pharma Out Of Orbit, But Ready For Relaunch (Seeking Alpha) -8.52%
Apr-09-25 10:55AM	Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.73%
Apr-03-25 07:00AM	Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -11.75%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -12.89%
Mar-26-25 10:40AM	Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? (InsiderMonkey) -5.88%
Feb-27-25 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jan-02-25 04:00PM	Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 08:05AM	Wedbush starts Rocket Pharmaceuticals with Outperform into inflection year (TipRanks)
Dec-18-24 02:16PM	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' (Investopedia)
Dec-11-24 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)
Nov-08-24 07:00AM	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-07-24 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Gen. CounselMr. Martin Louis Wilson J.D.

Chief Operating OfficerMr. Christopher Stevens

VP of FinanceMr. John C. Militello CPA

Chief Science & Gene Therapy OfficerDr. Jonathan Schwartz M.D.

L.L.M.Ms. Meg Dodge J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Gaurav	CEO	May 19 '26	Sale	3.01	2,409	7,261	1,040,918	May 21 04:06 PM
Wilson Martin	General Counsel	May 19 '26	Sale	3.01	662	1,995	677,977	May 21 04:06 PM
Militello John	See Remarks	May 19 '26	Sale	3.01	384	1,157	89,780	May 21 04:06 PM
Shah Gaurav	Officer	May 21 '26	Proposed Sale	3.09	55,684	171,821		May 21 03:40 PM
Shah Gaurav	Officer	May 19 '26	Proposed Sale	3.01	2,409	7,262		May 19 03:38 PM
Militello John	Officer	May 19 '26	Proposed Sale	3.01	384	1,158		May 19 03:33 PM
Wilson Martin	Officer	May 19 '26	Proposed Sale	3.01	662	1,996		May 19 03:20 PM
Wilson Martin	General Counsel	May 13 '26	Sale	3.61	3,361	12,120	678,639	May 14 04:22 PM
Shah Gaurav	CEO	May 13 '26	Sale	3.61	2,728	9,837	1,043,327	May 14 04:19 PM
Militello John	See Remarks	May 13 '26	Sale	3.61	855	3,083	90,164	May 14 04:16 PM
Wilson Martin	Officer	May 13 '26	Proposed Sale	3.61	3,361	12,118		May 13 03:15 PM
Shah Gaurav	Officer	May 13 '26	Proposed Sale	3.61	2,728	9,836		May 13 03:13 PM
Militello John	Officer	May 13 '26	Proposed Sale	3.61	855	3,083		May 13 03:10 PM
Chaudhuri Sarbani	See Remarks	May 07 '26	Sale	3.84	17,650	67,741	267,510	May 11 07:48 PM
Chaudhuri Sarbani	Officer	May 07 '26	Proposed Sale	3.84	17,650	67,741		May 07 03:14 PM
Militello John	See Remarks	Feb 18 '26	Sale	3.34	1,157	3,862	91,019	Feb 20 04:31 PM
Shah Gaurav	CEO	Feb 18 '26	Sale	3.34	5,990	19,995	1,046,055	Feb 20 04:26 PM
Wilson Martin	General Counsel	Feb 18 '26	Sale	3.34	1,376	4,593	682,000	Feb 20 04:09 PM
Wilson Martin	General Counsel	Feb 13 '26	Sale	3.31	12,253	40,582	683,376	Feb 18 05:42 PM
Militello John	See Remarks	Feb 13 '26	Sale	3.31	3,726	12,341	92,176	Feb 18 05:38 PM
Shah Gaurav	CEO	Feb 13 '26	Sale	3.31	12,279	40,668	1,052,045	Feb 18 05:33 PM
Militello John	Officer	Feb 18 '26	Proposed Sale	3.34	1,157	3,863		Feb 18 04:58 PM
Wilson Martin	Officer	Feb 18 '26	Proposed Sale	3.34	1,376	4,594		Feb 18 04:50 PM
Shah Gaurav	Officer	Feb 18 '26	Proposed Sale	3.34	5,990	19,998		Feb 18 04:50 PM
Wilson Martin	Officer	Feb 13 '26	Proposed Sale	3.31	12,253	40,583		Feb 13 04:31 PM
Shah Gaurav	Officer	Feb 13 '26	Proposed Sale	3.31	12,279	40,669		Feb 13 03:55 PM
Schwartz Jonathan David	Officer	Feb 13 '26	Proposed Sale	3.31	14,508	48,052		Feb 13 03:53 PM
Militello John	Officer	Feb 13 '26	Proposed Sale	3.31	3,726	12,341		Feb 13 03:39 PM
Bjork Elisabeth	Director	Jan 02 '26	Buy	3.44	10,000	34,400	50,000	Jan 06 04:05 PM
Schwartz Jonathan David	See Remarks	Nov 18 '25	Sale	2.98	2,545	7,592	299,064	Nov 20 04:05 PM
Shah Gaurav	CEO	Nov 18 '25	Sale	2.98	6,276	18,721	778,296	Nov 20 04:05 PM
Militello John	See Remarks	Nov 18 '25	Sale	2.98	1,086	3,240	65,920	Nov 20 04:05 PM
Wilson Martin	General Counsel	Nov 18 '25	Sale	2.98	1,646	4,910	383,816	Nov 20 04:05 PM
Schwartz Jonathan David	Officer	Nov 18 '25	Proposed Sale	2.98	2,545	7,591		Nov 18 03:57 PM
Shah Gaurav	Officer	Nov 18 '25	Proposed Sale	2.98	6,276	18,720		Nov 18 03:26 PM
Militello John	Officer	Nov 18 '25	Proposed Sale	2.98	1,086	3,239		Nov 18 03:16 PM
Wilson Martin	Officer	Nov 18 '25	Proposed Sale	2.98	1,646	4,910		Nov 18 03:16 PM
Militello John	See Remarks	Oct 14 '25	Sale	3.96	28,918	114,581	67,006	Oct 16 04:01 PM
Militello John	Officer	Oct 14 '25	Proposed Sale	3.96	28,918	114,581		Oct 14 12:29 PM
Bjork Elisabeth	Director	Aug 27 '25	Buy	3.41	10,000	34,100	40,000	Aug 27 08:54 PM
Militello John	See Remarks	Aug 18 '25	Sale	3.06	699	2,142	56,285	Aug 20 05:00 PM
Militello John	See Remarks	Aug 19 '25	Sale	3.00	361	1,082	55,924	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 18 '25	Sale	3.06	1,680	5,149	222,414	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 19 '25	Sale	3.00	805	2,412	221,609	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 18 '25	Sale	3.06	1,004	3,077	136,050	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 19 '25	Sale	3.00	588	1,762	135,462	Aug 20 05:00 PM
Wilson Martin	Officer	Aug 19 '25	Proposed Sale	3.00	588	1,762		Aug 19 03:33 PM
Schwartz Jonathan David	Officer	Aug 19 '25	Proposed Sale	3.00	805	2,412		Aug 19 03:28 PM
Militello John	Officer	Aug 19 '25	Proposed Sale	3.00	361	1,082		Aug 19 03:28 PM
Schwartz Jonathan David	See Remarks	Aug 14 '25	Sale	3.02	11,161	33,695	224,094	Aug 18 04:35 PM
Militello John	See Remarks	Aug 14 '25	Sale	3.02	7,043	21,263	56,984	Aug 18 04:35 PM
Wilson Martin	General Counsel	Aug 14 '25	Sale	3.02	12,109	36,557	137,054	Aug 18 04:35 PM
Wilson Martin	Officer	Aug 18 '25	Proposed Sale	3.07	1,004	3,077		Aug 18 03:24 PM
Militello John	Officer	Aug 18 '25	Proposed Sale	3.07	699	2,143		Aug 18 03:10 PM
Schwartz Jonathan David	Officer	Aug 18 '25	Proposed Sale	3.07	1,680	5,150		Aug 18 03:10 PM
Militello John	Officer	Aug 14 '25	Proposed Sale	3.02	7,043	21,261		Aug 14 05:55 PM
Wilson Martin	Officer	Aug 14 '25	Proposed Sale	3.02	12,109	36,553		Aug 14 05:47 PM
Schwartz Jonathan David	Officer	Aug 14 '25	Proposed Sale	3.02	11,161	33,692		Aug 14 05:44 PM
Ondrey Aaron	Chief Financial Officer	Jul 03 '25	Sale	2.88	1,477	4,257	128,173	Jul 08 04:05 PM
Ondrey Aaron	Officer	Jul 03 '25	Proposed Sale	2.88	1,477	4,256		Jul 03 03:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RCKT

Rocket Pharmaceuticals Inc

Upgrade your Finviz experience